|
|
News Breaks | | | | February 28, 2013 | | 07:15 EDT |  | ARWR | ArrowHead Research receives notice of patent allowance
Arrowhead Research Corporation announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/336,028 entitled, “In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages.” The company has previously reported target gene knockdown of 99% in monkeys after a single subcutaneous injection of 1 mg/kg, with >80% knockdown for 3 months. Additional data will be reported at upcoming scientific conferences and through peer-reviewed publications, the company said. | |
|
News For ARWR From The Last 14 Days Check below for free stories on ARWR the last two weeks. |
|
|
| May 13, 2013 | | 16:39 EDT | | ARWR | Sabby reports 6.99% passive stake in ArrowHead Research
| | | May 9, 2013 | | 17:19 EDT | | ARWR | RA Capital reports 9.9% passive stake in ArrowHead Research
 Subscribe for More Information | | | 16:45 EDT | | ARWR | Camber Capital reports 9.9% passive stake in ArrowHead Research
| | | May 7, 2013 | | 07:31 EDT | | ARWR | ArrowHead Research receives notice of allowance from USPTO
Arrowhead Research announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office, or USPTO, for U.S. Patent Application Number 13/326,433 entitled, " Peptide-Based In Vivo siRNA Delivery System." The allowed claims specifically protect the use of targeted melittin or melittin-like peptides to facilitate delivery of siRNA conjugates to hepatocytes. This new patent protection covers the composition of the Dynamic Polyconjugate, or DPC, delivery system used in Arrowhead's RNAi-based drug candidate, ARC-520, against chronic hepatitis B virus infection. | |
|
|
|
|
|
|
